D. Henderson

Creating a potential diagnostic for prostate cancer risk stratification (InformMDx™) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7).

M. Houslay, C. Bangma, D. J. Henderson, 2019, Clinical science.

Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression

L. F. Waanders, D. van Strijp, G. Jenster, 2015, British Journal of Cancer.

Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases

G. Baillie, M. Houslay, A. Ong, 2019, Proceedings of the National Academy of Sciences.

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells

G. Jenster, G. Baillie, M. Houslay, 2014, British Journal of Cancer.

The cAMP phosphodiesterase-4 D 7 ( PDE 4 D 7 ) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells

G. Jenster, G. Baillie, M. Houslay, 2014 .

Mitotic activation of the DISC1-inducible cyclic AMP phosphodiesterase-4D9 (PDE4D9), through multi-site phosphorylation, influences cell cycle progression.

E. Hill, G. Baillie, A. Dunlop, 2014, Cellular signalling.

A cAMP signalosome in primary cilia drives gene expression and kidney cyst formation

G. Pazour, Dagmar Wachten, H. Theis, 2022, EMBO reports.

The β-NAD+ salvage pathway and PKC-mediated signaling influence localized PARP-1 activity and CTCF Poly(ADP)ribosylation

J. Miranda, B. Emerson, D. J. Henderson, 2017, Oncotarget.